DUNDAS, ON, May 12 /PRNewswire/ - Anne Tomalin, President of CanReg Inc., is pleased to announce that Dayton T. Reardan, Ph.D., RAC has joined CanReg as Executive Advisory Strategist to assist client firms with their US regulatory needs. Dr. Reardan has held executive positions with small to medium sized public and private biotechnology and pharmaceutical firms. During this time, his focus has been on directing and managing regulatory affairs, most recently with the US-based companies Orphan Medical Inc. and Eleos Inc.
Dr. Reardan has extensive experience in the arena of orphan drug development, having participated in more than 15 orphan drug designations in the United States and Europe resulting in 12 approved marketing indications (US, Europe, Canada, Israel, Japan, South Africa, Australia, New Zealand). Six of these were for new chemical entities with the FDA, including the many supplemental label expansions, and their associative regulatory investigational filings. Dr. Reardan has been twice awarded the FDA Commissioner's Special Citation for his contributions to orphan drug development and registration.
CanReg has supported the world-wide pharmaceutical, biotechnology and device industry representing companies, large and small, with their FDA, Health Canada, European and world-wide regulatory requirements. Dayton Reardan can be reached at firstname.lastname@example.org or by calling CanReg at 1 866 722-6734.
About CanReg Inc.
CanReg is a company dedicated to strategic consulting and tactical regulatory services in the United States, Canada, and Europe. More than 100 in-house consultants and staff support our pharmaceutical, biotechnology and medical device clients in these markets, from investigational products through registration and post-approval world-wide.
|SOURCE CanReg Inc.|
Copyright©2009 PR Newswire.
All rights reserved